CA2394358A1 - Technologie de micro-matrice de tissus a haut debit et applications - Google Patents
Technologie de micro-matrice de tissus a haut debit et applications Download PDFInfo
- Publication number
- CA2394358A1 CA2394358A1 CA002394358A CA2394358A CA2394358A1 CA 2394358 A1 CA2394358 A1 CA 2394358A1 CA 002394358 A CA002394358 A CA 002394358A CA 2394358 A CA2394358 A CA 2394358A CA 2394358 A1 CA2394358 A1 CA 2394358A1
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- biological
- specimens
- samples
- sections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012775 microarray technology Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 252
- 238000004458 analytical method Methods 0.000 claims abstract description 206
- 238000003491 array Methods 0.000 claims abstract description 55
- 238000002493 microarray Methods 0.000 claims description 207
- 206010028980 Neoplasm Diseases 0.000 claims description 172
- 239000000523 sample Substances 0.000 claims description 142
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 239000003153 chemical reaction reagent Substances 0.000 claims description 81
- 239000000090 biomarker Substances 0.000 claims description 77
- 230000001413 cellular effect Effects 0.000 claims description 54
- 239000000758 substrate Substances 0.000 claims description 52
- 239000012472 biological sample Substances 0.000 claims description 50
- 230000000875 corresponding effect Effects 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 108020004414 DNA Proteins 0.000 claims description 28
- 238000001514 detection method Methods 0.000 claims description 27
- 238000011156 evaluation Methods 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 26
- 238000003860 storage Methods 0.000 claims description 25
- 239000003550 marker Substances 0.000 claims description 24
- 238000009396 hybridization Methods 0.000 claims description 23
- 238000012545 processing Methods 0.000 claims description 22
- 238000009826 distribution Methods 0.000 claims description 20
- 108020004999 messenger RNA Proteins 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 18
- 238000010276 construction Methods 0.000 claims description 17
- 238000003745 diagnosis Methods 0.000 claims description 17
- 238000003384 imaging method Methods 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 15
- 239000002853 nucleic acid probe Substances 0.000 claims description 15
- 238000003908 quality control method Methods 0.000 claims description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 238000010191 image analysis Methods 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- 238000011161 development Methods 0.000 claims description 13
- 230000001613 neoplastic effect Effects 0.000 claims description 13
- 238000004080 punching Methods 0.000 claims description 13
- 230000007170 pathology Effects 0.000 claims description 12
- 238000007479 molecular analysis Methods 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 238000004891 communication Methods 0.000 claims description 10
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 230000002596 correlated effect Effects 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 238000003196 serial analysis of gene expression Methods 0.000 claims description 10
- 230000000052 comparative effect Effects 0.000 claims description 9
- 230000003287 optical effect Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 230000001900 immune effect Effects 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 230000009870 specific binding Effects 0.000 claims description 7
- 238000001228 spectrum Methods 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000001712 DNA sequencing Methods 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 238000000636 Northern blotting Methods 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 230000001276 controlling effect Effects 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 238000003119 immunoblot Methods 0.000 claims description 4
- 238000001114 immunoprecipitation Methods 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 238000012549 training Methods 0.000 claims description 4
- 238000012800 visualization Methods 0.000 claims description 4
- 238000012287 DNA Binding Assay Methods 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 238000002105 Southern blotting Methods 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 238000002331 protein detection Methods 0.000 claims description 3
- 238000001742 protein purification Methods 0.000 claims description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 2
- 230000002380 cytological effect Effects 0.000 claims description 2
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 238000007899 nucleic acid hybridization Methods 0.000 claims 5
- 238000010827 pathological analysis Methods 0.000 claims 1
- 238000012335 pathological evaluation Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 624
- 238000010186 staining Methods 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 40
- 230000014509 gene expression Effects 0.000 description 33
- 230000002055 immunohistochemical effect Effects 0.000 description 22
- 238000013459 approach Methods 0.000 description 21
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 18
- 239000012188 paraffin wax Substances 0.000 description 17
- 206010006187 Breast cancer Diseases 0.000 description 16
- 208000026310 Breast neoplasm Diseases 0.000 description 15
- 239000012620 biological material Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 108010078791 Carrier Proteins Proteins 0.000 description 14
- 108700020796 Oncogene Proteins 0.000 description 14
- 230000002962 histologic effect Effects 0.000 description 13
- 230000001575 pathological effect Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 206010005003 Bladder cancer Diseases 0.000 description 11
- 230000004544 DNA amplification Effects 0.000 description 11
- 238000011953 bioanalysis Methods 0.000 description 10
- 238000007901 in situ hybridization Methods 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 102000015694 estrogen receptors Human genes 0.000 description 9
- 108010038795 estrogen receptors Proteins 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000043276 Oncogene Human genes 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000000877 morphologic effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 201000005112 urinary bladder cancer Diseases 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 201000001531 bladder carcinoma Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 239000003147 molecular marker Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011862 kidney biopsy Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000006311 Cyclin D1 Human genes 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000009799 cystectomy Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000024312 invasive carcinoma Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000005305 organ development Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 241001270131 Agaricus moelleri Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 102000002247 NADPH Dehydrogenase Human genes 0.000 description 1
- 108010014870 NADPH Dehydrogenase Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000007768 histopathological growth pattern Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 238000009801 radical cystectomy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000021419 recognition of apoptotic cell Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0099—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor comprising robots or similar manipulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N1/31—Apparatus therefor
- G01N1/312—Apparatus therefor for samples mounted on planar substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00279—Features relating to reactor vessels
- B01J2219/00306—Reactor vessels in a multiple arrangement
- B01J2219/00313—Reactor vessels in a multiple arrangement the reactor vessels being formed by arrays of wells in blocks
- B01J2219/00315—Microtiter plates
- B01J2219/00317—Microwell devices, i.e. having large numbers of wells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00513—Essentially linear supports
- B01J2219/0052—Essentially linear supports in the shape of elongated tubes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00513—Essentially linear supports
- B01J2219/0052—Essentially linear supports in the shape of elongated tubes
- B01J2219/00522—Essentially linear supports in the shape of elongated tubes in a multiple parallel arrangement
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00585—Parallel processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00585—Parallel processes
- B01J2219/00587—High throughput processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00664—Three-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00673—Slice arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
- C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/02—Devices for withdrawing samples
- G01N1/04—Devices for withdrawing samples in the solid state, e.g. by cutting
- G01N1/06—Devices for withdrawing samples in the solid state, e.g. by cutting providing a thin slice, e.g. microtome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/02—Devices for withdrawing samples
- G01N1/04—Devices for withdrawing samples in the solid state, e.g. by cutting
- G01N1/08—Devices for withdrawing samples in the solid state, e.g. by cutting involving an extracting tool, e.g. core bit
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/36—Embedding or analogous mounting of samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/36—Embedding or analogous mounting of samples
- G01N2001/368—Mounting multiple samples in one block, e.g. TMA [Tissue Microarrays]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/00029—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor provided with flat sample substrates, e.g. slides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Robotics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un procédé et un appareil à haut débit et à grande échelle déterminant le profil moléculaire de spécimens de tissus par recherche d'un spécimen de tissu de donneur dans une matrice de spécimens de donneurs consistant à mettre en place un échantillon du spécimen de donneur dans un emplacement attribué d'une matrice de récipients, à fournir des copies de la matrice, à procéder à une analyse biologique différente de chaque copie, et à stocker les résultats d'analyse. Les résultats sont comparés pour déterminer s'il existe des corrélations ou de différences entre les résultats des différentes analyses biologiques à chaque emplacement attribué. Ces résultats sont aussi comparés à des informations cliniques du patient humain à partir duquel provient le tissu. Les résultats d'analyses similaires sur des sections correspondantes de la matrice sont utilisées en tant que dispositifs de contrôle de qualité en soumettant, par exemple, les matrices à une procédure de recherche simultanée unique. Une interprétation uniforme des matrices est obtenue, et comparée aux interprétations des différents observateurs.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17046199P | 1999-12-13 | 1999-12-13 | |
US60/170,461 | 1999-12-13 | ||
US17126299P | 1999-12-15 | 1999-12-15 | |
US60/171,262 | 1999-12-15 | ||
PCT/US2000/034043 WO2001042796A1 (fr) | 1999-12-13 | 2000-12-13 | Technologie de micro-matrice de tissus a haut debit et applications |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2394358A1 true CA2394358A1 (fr) | 2001-06-14 |
Family
ID=26866105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002394358A Abandoned CA2394358A1 (fr) | 1999-12-13 | 2000-12-13 | Technologie de micro-matrice de tissus a haut debit et applications |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1238286A1 (fr) |
AU (1) | AU782452B2 (fr) |
CA (1) | CA2394358A1 (fr) |
WO (1) | WO2001042796A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4232792A4 (fr) * | 2020-10-23 | 2024-10-30 | Clarapath Inc | Diagnostics préliminaires de sections de tissu coupé |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020168639A1 (en) * | 2000-09-22 | 2002-11-14 | Muraca Patrick J. | Profile array substrates |
AU2001269835A1 (en) * | 2000-12-13 | 2002-06-24 | The Government Of The United Staes Of America As Represented By The Secretary Of The Department Of Health And Human Services. | Method and system for processing regions of interest for objects comprising biological material |
US6466690C1 (en) * | 2000-12-19 | 2008-11-18 | Bacus Res Lab Inc | Method and apparatus for processing an image of a tissue sample microarray |
US20020150966A1 (en) * | 2001-02-09 | 2002-10-17 | Muraca Patrick J. | Specimen-linked database |
US7468242B2 (en) | 2001-11-05 | 2008-12-23 | Medgenics, Inc. | Dermal micro organs, methods and apparatuses for producing and using the same |
US8501396B2 (en) | 2001-11-05 | 2013-08-06 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
US7584240B2 (en) | 2001-11-07 | 2009-09-01 | Genvault Corporation | Automated biological sample archive for storage, retrieval and analysis of large numbers of samples for remote clients |
US20030087425A1 (en) * | 2001-11-07 | 2003-05-08 | Eggers Mitchell D | Sample carrier |
US20030165263A1 (en) | 2002-02-19 | 2003-09-04 | Hamer Michael J. | Histological assessment |
CA2482441C (fr) | 2002-04-15 | 2010-06-22 | Ventana Medical Systems, Inc. | Systeme de coloration de lame automatique a volume de traitement eleve |
HU2464U (en) * | 2002-06-25 | 2003-03-28 | Szekeres Gyoergy Dr | Hand instrument set for constructing tissue array |
JP2005533102A (ja) * | 2002-07-12 | 2005-11-04 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム | 微小器官によって生物学的プロセスを誘発する方法と装置 |
US7718442B2 (en) | 2002-11-22 | 2010-05-18 | Genvault Corporation | Sealed sample storage element system and method |
EP2377404A1 (fr) | 2003-05-01 | 2011-10-19 | Medgenics, Inc. | Micro-organe dermique qui est un explant de tissus vivants |
DE10322282A1 (de) * | 2003-05-16 | 2004-12-16 | Ogham Gmbh | Verfahren zur automatischen Genotypisierung |
US8068988B2 (en) | 2003-09-08 | 2011-11-29 | Ventana Medical Systems, Inc. | Method for automated processing of digital images of tissue micro-arrays (TMA) |
WO2005027015A2 (fr) | 2003-09-10 | 2005-03-24 | Bioimagene, Inc. | Procede et systeme d'analyse quantitative d'echantillons biologiques |
DE10344284A1 (de) * | 2003-09-24 | 2005-05-04 | Keyneurotek Ag | Vorrichtung und Verfahren zur automatisierten Durchführung von Laborarbeitsschritten |
WO2005114578A1 (fr) * | 2004-05-21 | 2005-12-01 | Bioimagene, Inc. | Procede et systeme de quantification automatisee d'une analyse d'image numerique d'un jeu ordonne de microechantillons de tissu (tma) |
CA2567720A1 (fr) | 2004-05-24 | 2005-12-08 | Genvault Corporation | Stockage proteique stable et stockage d'acides nucleiques stable sous forme recuperable |
CN1306258C (zh) * | 2004-06-22 | 2007-03-21 | 浙江大学 | 一种组织芯片制备方法及其装置 |
US7405056B2 (en) | 2005-03-02 | 2008-07-29 | Edward Lam | Tissue punch and tissue sample labeling methods and devices for microarray preparation, archiving and documentation |
WO2006127967A2 (fr) | 2005-05-25 | 2006-11-30 | Massachusetts Institute Of Technology | Systemes d'imagerie multifocaux et procedes associes |
CN101610793B (zh) | 2006-09-14 | 2012-10-24 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
CN102177237B (zh) | 2008-09-12 | 2013-10-30 | 金沃特公司 | 用于贮存和稳定生物分子的基质和介质 |
DE102009036239A1 (de) | 2009-08-05 | 2011-05-05 | Vogel, Ulrich, Dr.med. | Gußform zur Herstellung von Materialblöcken mit multiplen Aufnahmelöchern zur Einstellung von Untersuchungsproben |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
CN105385756B (zh) | 2010-04-05 | 2020-12-25 | 普罗格诺西斯生物科学公司 | 空间编码的生物学测定 |
TWI427281B (zh) * | 2011-03-23 | 2014-02-21 | Taichung Veterans General Hospital | 組織檢體的預處理方法 |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
US9164015B2 (en) * | 2012-06-29 | 2015-10-20 | General Electric Company | Systems and methods for processing and imaging of biological samples |
US9817221B2 (en) | 2012-06-29 | 2017-11-14 | General Electric Company | Systems and methods for processing and imaging of biological samples |
EP2909337B1 (fr) | 2012-10-17 | 2019-01-09 | Spatial Transcriptomics AB | Procédés et produit d'optimisation de la détection localisée ou spatiale de l'expression génique dans un échantillon de tissu |
JP6118071B2 (ja) * | 2012-11-08 | 2017-04-19 | サクラファインテックジャパン株式会社 | ブロック保管装置及び自動薄切装置 |
EP3514224B1 (fr) | 2012-11-26 | 2022-03-16 | Fraunhofer USA, Inc. | Système et procédé d'échantillonnage automatique de tissus végétaux |
CA2893590C (fr) | 2012-12-14 | 2023-10-10 | The J. David Gladstone Institutes | Systemes de microscopie robotique automatisee |
US9091621B2 (en) * | 2013-04-05 | 2015-07-28 | GGB Company | Multiple slide processing apparatus |
DK3013984T3 (da) | 2013-06-25 | 2023-06-06 | Prognosys Biosciences Inc | Metode til bestemmelse af spatiale mønstre i biologiske targets i en prøve |
US11016007B2 (en) * | 2014-04-01 | 2021-05-25 | Bd Kiestra B.V. | System and method for the automated preparation of biological samples |
WO2016145366A1 (fr) * | 2015-03-11 | 2016-09-15 | Timothy Ragan | Système et méthodes de coloration et d'imagerie en série |
ES2972835T3 (es) | 2015-04-10 | 2024-06-17 | 10X Genomics Sweden Ab | Análisis multiplex de especímenes biológicos de ácidos nucleicos espacialmente distinguidos |
RU176694U1 (ru) * | 2016-11-18 | 2018-01-25 | Общество с ограниченной ответственностью "Национальный БиоСервис" | Реципиентный блок для производства тканевых микрочипов |
WO2018195353A1 (fr) * | 2017-04-20 | 2018-10-25 | Biolyceum, Llc | Outil histopathologique à haut débit et procédés d'utilisation |
JP2021534509A (ja) * | 2018-08-22 | 2021-12-09 | ユニバーシティ オブ ピッツバーグ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーションUniversity Of Pittsburgh Of The Commonwealth System Of Higher Education | マイクロドメインをフィンガープリントするための、空間的に共登録されたゲノム及びイメージング(scorgi)データ要素 |
US11519033B2 (en) | 2018-08-28 | 2022-12-06 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample |
WO2020123311A2 (fr) | 2018-12-10 | 2020-06-18 | 10X Genomics, Inc. | Résolution de réseaux spatiaux à l'aide d'une déconvolution |
US11649485B2 (en) | 2019-01-06 | 2023-05-16 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
US11926867B2 (en) | 2019-01-06 | 2024-03-12 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
EP3976820A1 (fr) | 2019-05-30 | 2022-04-06 | 10X Genomics, Inc. | Procédés de détection de l'hétérogénéité spatiale d'un échantillon biologique |
WO2020256580A1 (fr) * | 2019-06-19 | 2020-12-24 | Общество с ограниченной ответственностью "Национальный БиоСервис" | Unité matricielle de production de micropuces tissulaires |
RU196594U1 (ru) * | 2019-06-19 | 2020-03-06 | Общество с ограниченной ответственностью "Национальный БиоСервис" | Матричный блок для изготовления тканевых микрочипов |
EP4025711A2 (fr) | 2019-11-08 | 2022-07-13 | 10X Genomics, Inc. | Amélioration de la spécificité de la liaison d'un analyte |
RU198106U1 (ru) * | 2019-12-04 | 2020-06-18 | Общество с ограниченной ответственностью "Национальный БиоСервис" | Матричный блок для изготовления тканевых микрочипов |
RU201746U1 (ru) * | 2019-12-04 | 2020-12-31 | Общество с ограниченной ответственностью "Национальный БиоСервис" | Матричный блок для изготовления тканевых микрочипов |
EP4081656A1 (fr) | 2019-12-23 | 2022-11-02 | 10X Genomics, Inc. | Compositions et méthodes d'utilisation d'échantillons biologiques fixés dans des dosages basés sur des compartiments |
FI3891300T3 (fi) | 2019-12-23 | 2023-05-10 | 10X Genomics Inc | Menetelmät spatiaalista analyysiä varten rna-templatoitua ligaatiota käyttäen |
US11702693B2 (en) | 2020-01-21 | 2023-07-18 | 10X Genomics, Inc. | Methods for printing cells and generating arrays of barcoded cells |
US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
US12076701B2 (en) | 2020-01-31 | 2024-09-03 | 10X Genomics, Inc. | Capturing oligonucleotides in spatial transcriptomics |
US11898205B2 (en) | 2020-02-03 | 2024-02-13 | 10X Genomics, Inc. | Increasing capture efficiency of spatial assays |
US12110541B2 (en) | 2020-02-03 | 2024-10-08 | 10X Genomics, Inc. | Methods for preparing high-resolution spatial arrays |
US11732300B2 (en) | 2020-02-05 | 2023-08-22 | 10X Genomics, Inc. | Increasing efficiency of spatial analysis in a biological sample |
US12129516B2 (en) | 2020-02-07 | 2024-10-29 | 10X Genomics, Inc. | Quantitative and automated permeabilization performance evaluation for spatial transcriptomics |
US11891654B2 (en) | 2020-02-24 | 2024-02-06 | 10X Genomics, Inc. | Methods of making gene expression libraries |
ES2965354T3 (es) | 2020-04-22 | 2024-04-12 | 10X Genomics Inc | Métodos para análisis espacial que usan eliminación de ARN elegido como diana |
EP4153775B1 (fr) | 2020-05-22 | 2024-07-24 | 10X Genomics, Inc. | Mesure spatio-temporelle simultanée de l'expression génique et de l'activité cellulaire |
WO2021237087A1 (fr) | 2020-05-22 | 2021-11-25 | 10X Genomics, Inc. | Analyse spatiale pour détecter des variants de séquence |
WO2021242834A1 (fr) | 2020-05-26 | 2021-12-02 | 10X Genomics, Inc. | Procédé de réinitialisation d'un réseau |
US12031177B1 (en) | 2020-06-04 | 2024-07-09 | 10X Genomics, Inc. | Methods of enhancing spatial resolution of transcripts |
EP4421186A3 (fr) | 2020-06-08 | 2024-09-18 | 10X Genomics, Inc. | Procédés de détermination d'une marge chirurgicale et procédés d'utilisation de ceux-ci |
WO2021252591A1 (fr) | 2020-06-10 | 2021-12-16 | 10X Genomics, Inc. | Procédés de détermination d'un emplacement d'un analyte dans un échantillon biologique |
EP4172362B1 (fr) | 2020-06-25 | 2024-09-18 | 10X Genomics, Inc. | Analyse spatiale de la méthylation de l'adn |
US11761038B1 (en) | 2020-07-06 | 2023-09-19 | 10X Genomics, Inc. | Methods for identifying a location of an RNA in a biological sample |
US11981960B1 (en) | 2020-07-06 | 2024-05-14 | 10X Genomics, Inc. | Spatial analysis utilizing degradable hydrogels |
US11981958B1 (en) | 2020-08-20 | 2024-05-14 | 10X Genomics, Inc. | Methods for spatial analysis using DNA capture |
US11926822B1 (en) | 2020-09-23 | 2024-03-12 | 10X Genomics, Inc. | Three-dimensional spatial analysis |
US11827935B1 (en) | 2020-11-19 | 2023-11-28 | 10X Genomics, Inc. | Methods for spatial analysis using rolling circle amplification and detection probes |
WO2022140028A1 (fr) | 2020-12-21 | 2022-06-30 | 10X Genomics, Inc. | Procédés, compositions et systèmes pour capturer des sondes et/ou des codes à barres |
CN113351271B (zh) * | 2021-05-11 | 2022-08-09 | 武汉明德生物科技股份有限公司 | 一种pcr分析仪的控制方法及控制器 |
EP4347879A1 (fr) | 2021-06-03 | 2024-04-10 | 10X Genomics, Inc. | Procédés, compositions, kits et systèmes pour améliorer la capture d'analytes pour une analyse spatiale |
EP4196605A1 (fr) | 2021-09-01 | 2023-06-21 | 10X Genomics, Inc. | Procédés, compositions et kits pour bloquer une sonde de capture sur un réseau spatial |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5355439A (en) * | 1991-08-05 | 1994-10-11 | Bio Tek Instruments | Method and apparatus for automated tissue assay |
AU5873294A (en) * | 1992-12-23 | 1994-07-19 | Board Of Regents Of The University Of Nebraska, The | Method for automatic testing of laboratory specimens |
US6151405A (en) * | 1996-11-27 | 2000-11-21 | Chromavision Medical Systems, Inc. | System and method for cellular specimen grading |
US5746855A (en) * | 1996-10-24 | 1998-05-05 | Advanced Pathology Systems, Inc. | Method and apparatus for automatic archival storage of tissue sample sections cut from a sample block |
CA2318789C (fr) * | 1998-02-25 | 2011-05-10 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Arrangements cellulaires permettant une definition de profil moleculaire rapide |
-
2000
- 2000-12-13 WO PCT/US2000/034043 patent/WO2001042796A1/fr not_active Application Discontinuation
- 2000-12-13 AU AU24329/01A patent/AU782452B2/en not_active Ceased
- 2000-12-13 CA CA002394358A patent/CA2394358A1/fr not_active Abandoned
- 2000-12-13 EP EP00988081A patent/EP1238286A1/fr not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4232792A4 (fr) * | 2020-10-23 | 2024-10-30 | Clarapath Inc | Diagnostics préliminaires de sections de tissu coupé |
Also Published As
Publication number | Publication date |
---|---|
WO2001042796A1 (fr) | 2001-06-14 |
EP1238286A1 (fr) | 2002-09-11 |
AU782452B2 (en) | 2005-07-28 |
AU2432901A (en) | 2001-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU782452B2 (en) | High-throughput tissue microarray technology and applications | |
US20030215936A1 (en) | High-throughput tissue microarray technology and applications | |
US20040085443A1 (en) | Method and system for processing regions of interest for objects comprising biological material | |
US6699710B1 (en) | Tumor tissue microarrays for rapid molecular profiling | |
AU754047B2 (en) | Tumor tissue microarrays for rapid molecular profiling | |
US9284610B2 (en) | Cellular arrays and methods of detecting and using genetic disorder markers | |
EP1066517B1 (fr) | Arrangements cellulaires permettant une definition de profil moleculaire rapide | |
Moch et al. | Tissue microarrays: what will they bring to molecular and anatomic pathology? | |
Kumar et al. | Tissue microarrays: a practical guide | |
CA2431067A1 (fr) | Procede et systeme servant a traiter des zones d'interet d'objets contenant une substance biologique | |
Lee et al. | Tissue array methods for high-throughput clinicopathologic research | |
Moskaluk | Molecular pathology laboratory of the future |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |